1-3 of 3
Marcelo Lima Ribeiro
Close
Sort by
Journal Articles

Narazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant Mantle Cell Lymphoma

Nuria Profitos-Peleja, Marcelo Lima Ribeiro, Jeronimo Parra, Miranda Fernandez-Serrano, Pau Marin-Escudero, Joan Josep Bech, Carolina De La Torre, Adar Makovski Silverstein, Steve Cosenza, Steven M. Fruchtman, Manel Esteller, Gael Roue
Journal: Blood
Blood (2023) 142 (Supplement 1): 4181.
https://doi.org/10.1182/blood-2023-189838
Published: 2023
Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Miriam Verdú Bou, Maria Joao Baptista, Aleix Mendez Lopez, Gustavo Tapia, Marcelo Lima Ribeiro, Gaël Roué, Jose Luis Mate, Pau Abrisqueta, Mariana Bastos-Oreiro, Miguel Alcoceba, Eva González Barca, Fina Climent, Antonio Salar, Juan-Manuel Sancho, Fabian Frontzek, Annette M. Staiger, German Ott, Manuel Castro De Moura, Georg Lenz, Jose Tomas Navarro
Journal: Blood
Blood (2022) 140 (Supplement 1): 9266–9268.
https://doi.org/10.1182/blood-2022-168552
Published: 2022
Journal Articles

The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183

Emmanuel Normant, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, Pedro Blecua, Diana Reyes-Garau, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin, Gael Roue
Journal: Blood
Blood (2021) 138 (Supplement 1): 1196.
https://doi.org/10.1182/blood-2021-150570
Published: 2021